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In the present study, we investigated the effect of a Kampo medicine Goshajinkigan (GJG) on the
bortezomib-induced mechanical allodynia in von Frey test in rats. The single administration of tramadol
(10 mg/kg), GJG (1.0 g/kg) and its component processed Aconiti tuber (0.1 g/kg) signiﬁcantly reversed the
reduction in withdrawal threshold by bortezomib. These effects were abolished by the intrathecal in-
jection of nor-binaltorphimine (10 mg/body), kappa opioid receptor antagonist. These ﬁndings suggest
that kappa opioid receptor is involved in the effect of GJG on the bortezomib-induced mechanical
allodynia.
© 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Bortezomib, a proteasome inhibitor, is widely used for chemo-
therapy of multiple myeloma and mantle cell lymphoma. Borte-
zomib offers advantages in these cancers, but causes severe
peripheral neuropathy, which is mainly characterized by numbness
and painful paresthesia. These adverse effects decline in quality of
life, decrease the dose or discontinue the chemotherapy (1).
Although some analgesic drugs are used, there is no established
treatment for peripheral neuropathy induced by bortezomib.
Goshajinkigan (GJG), a Kampo medicine, is widely used to treat
limb pain, backache, numbness and diabetic- or chemotherapy-
induced neuropathy (2,3). A basic study of a rodent model of dia-
betic neuropathy revealed that the antinociceptive effect of GJG is
partly derived from the action of processed Aconiti tuber, one of the
components, and that it is based on stimulation of spinal kappa
opioid receptors (4). Recently, we reported that single administra-
tion of GJG reduced pain behaviors induced by oxaliplatin, a
platinum-based chemotherapeutic agent, in rats (5). However, the
effect of GJG on the bortezomib-induced painful neuropathy has
not been studied. Therefore, we investigated the effects of GJG and
Aconiti tuber on the bortezomib-induced pain behavior in rats.Kyushu University Hospital,
an. Tel.: þ81 92 642 5920;
.jp (N. Egashira).
rmacological Society.
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d/4.0/).Furthermore, we examined the involvement of kappa opioid re-
ceptor in the effects of GJG and Aconiti tuber.
Male SpragueeDawley rats weighing 200e250 g (Kyudo Co.,
Tosu) were used in the present study. Rats were housed in groups of
four to ﬁve per cages with lights on from 07:00 to 19:00 h. Animals
had free access to food and water in their home cages. All experi-
ments were performed under the Experimental Animals Care and
Use Committee of Kyushu University according to the National In-
stitutes of Health guidelines, and we followed the International
Association for the Study of Pain Committee for Research and
Ethical Issues guidelines for animal research (6).
GJG (Lot. No. 2090107010) was a generous gift from Tsumura &
Co. (Tokyo). Processed Aconiti tuber was obtained from Tsumura &
Co. GJG was a dried extract of the following raw materials:
Rehmanniae radix (Scrophulariaceae, prepared rehmannia root,
5.0 g), Achyranthis radix (Amaranthaceae, Achyranthes root, 3.0 g),
Corni fructus (Cornaceae, Cornus fruit, 3.0 g), Moutan cortex
(Ranunculaceae, mountain root bark, 3.0 g), Alismatis rhizoma
(Alismataceae, Alisma rhizome, 3.0 g), Dioscoreae rhizoma (Dio-
scoreaceae, Chinese yam, 3.0 g), Plantaginis semen (Plantaginaceae,
Plantago seeds, 3.0 g), Poria cocos (Polyporaceae, hoelen, 3.0 g),
processed Aconiti tuber (Ranunculaceae, prepared aconite root,
1.0 g), and Cinnamomi cortex (Lauraceae, cinnamon bark, 1.0 g).
Each plant material was authenticated by identiﬁcation of external
morphology and marker compounds of plants specimens, accord-
ing to the methods of the Japanese Pharmacopoeia and Tsumura &
Co's standard. The ten medical herbs were extracted with puriﬁed
water at 95 C for 1 h, and the extraction solution was separatednese Pharmacological Society. This is an open access article under the CC BY-NC-ND
Fig. 1. Effects of tramadol and Goshajinkigan (GJG) on bortezomib-induced mechanical
allodynia in von Frey test in rats. Bortezomib (0.2 mg/kg) was administered i.p. twice a
week for 2 weeks (on days 1, 4, 8, and 11) and drug evaluation was carried on days
12e15. Tramadol, GJG or vehicle (distilled water) was administered orally. von Frey test
was performed immediately before (0 min) and at 30, 60, 90, 120, and 150 min after
drug administration. Values are expressed as the mean ± S.E.M. of 6 animals. ##P < 0.01
compared with the 5% DMSO, *P < 0.05, **P < 0.01 compared with distilled water.
Fig. 2. Effects of Goshajinkigan (GJG) and processed Aconiti tuber on bortezomib-
induced mechanical allodynia in von Frey test in rats. Bortezomib (0.2 mg/kg) was
administered i.p. twice a week for 2 weeks (on days 1, 4, 8, and 11) and drug evaluation
was carried on days 12e15. GJG, Aconiti tuber or vehicle (distilled water) was
administered orally. von Frey test was performed immediately before (0 min) and at
30, 60, 90, 120, and 150 min after drug administration. Values are expressed as the
mean ± S.E.M. of 6e7 animals. #P < 0.05 compared with the 5% DMSO, **P < 0.01
compared with distilled water.
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under reduced pressure. Spray drying was used to produce a dried
extract powder. The yield of the extract was about 16.1%. They were
manufactured in compliance with the Japanese Pharmacopoeia
(Sixteenth Edition, JP16) under Good Manufacturing Practice
(GMP). The product information can be acquired in “KCONSORT”
(http://kconsort.umin.jp).
Tramadol hydrochloride and nor-binaltorphimine dihydro-
chloride were obtained from SigmaeAldrich, Inc. (St. Louis, MO,
USA). GJG and Aconiti tuber were suspended, and tramadol was
dissolved in distilled water. They were administered per os (p.o.) at
a volume of 3 mL/kg of body weight. Nor-binaltorphimine was
dissolved in saline (10 mg/20 mL) and injected intrathecally (i.t.) at a
volume of 20 mL/body. The doses of drugs were chosen based on
previous reports (4,5,7,8). Control animals received vehicle only via
the same route. Bortezomib was purchased from LC Laboratories
(Woburn, MA, USA) and dissolved in 5% dimethyl sulfoxide solu-
tion. Bortezomib (0.2 mg/kg) or vehicle was administered intra-
peritoneally (i.p.) twice a week for 2 weeks (on days 1, 4, 8, and 11)
at a volume of 1mL/kg of bodyweight. The administration schedule
and dose were based on clinical treatment (1.3 mg/m2 of bortezo-
mib on days 1, 4, 8, and 11).
Mechanical allodynia was assessed by von Frey test. Rats were
placed in a plastic box (20 17 13 cm)with awiremesh ﬂoor and
allowed to habituate for 30 min prior to testing. von Frey ﬁlaments
(The Touch Test Sensory Evaluator Set; Linton Instrumentation,
Diss, Norfolk, UK) with a range of 1e15 g bending force were
applied to the midplantar skin of each hind paw 6 times, with each
application held for 6 s. The paw withdrawal threshold was
determined by a modiﬁed up-down method (5).
To determine the therapeutic effects of the drugs on bortezomib-
induced mechanical allodynia, behavioral tests were assessed on
days 12e15 after the development of neuropathy. Tramadol, GJG,
Aconiti tuber or vehicle (distilledwater)was administered orally, and
von Frey test was performed immediately before (0 min) and 30, 60,
90, 120 and 150 after drug administration.
In order to examine the involvement of kappa opioid receptor,
GJG (1 g/kg), Aconiti tuber (0.1 g/kg) or vehicle was injected p.o.
60 min before the test. Nor-binaltorphimine (10 mg/body) was
injected i.t. 15 min before the test.
The data are shown as the mean ± S.E.M. Statistical analysis was
performed using the Student's t-test or one-way analysis of vari-
ance (ANOVA) followed by the TukeyeKramar test (Statview;
Abacus Concepts, Berkely, CA, USA) to determine differences be-
tween the groups. A probability level of P < 0.05 was accepted as
statistically signiﬁcant.
Bortezomib (0.2 mg/kg, i.p.) signiﬁcantly reduced the with-
drawal threshold compared with vehicle (P < 0.01 by Student's t-
test, Fig. 1). The single administration of tramadol (10 mg/kg, p.o.),
used as the positive control, signiﬁcantly reversed the bortezomib-
induced reduction in withdrawal threshold at 60 min after
administration (P < 0.05 by TukeyeKramer test). Similarly, the
single administration of GJG (1.0 g/kg, p.o.) signiﬁcantly increased
the reduced threshold by bortezomib at 60 min after administra-
tion (P < 0.01 by TukeyeKramer test), and these effects disappeared
120e150 min after administration. As shown in Fig. 2, the single
administration of Aconiti tuber (0.1 g/kg, p.o.) also signiﬁcantly
increased the withdrawal threshold to the same level as GJG (1.0 g/
kg, p.o.) at 60 min after administration (P < 0.01 by TukeyeKramer
test). At 120e150 min after administration these effects of GJG and
Aconiti tuber had disappeared.
The selective kappa opioid receptor antagonist nor-
binaltorphimine (10 mg/body, i.t.) completely reversed the in-
crease in withdrawal threshold by GJG (P < 0.05 by TukeyeKramer
test) or Aconiti tuber (P < 0.01 by TukeyeKramer test, Fig. 3). Inaddition, nor-binaltorphimine at the same dose alone did not affect
the paw withdrawal threshold (data not shown).
In the present study, we observed repeated administration of
bortezomib caused mechanical allodynia. Our data indicated single
administration of tramadol (10 mg/kg) had anti-allodynic effect on
the bortezomib-induced mechanical allodynia. These results are
consistent with the previous ﬁndings (7). Similarly, the single
administration of GJG (1 g/kg) exerted anti-allodynic effect on the
bortezomib-induced mechanical allodynia. Therefore, GJG may be
effective in the relief of painful neuropathy induced by bortezomib.
The present results showed the single administration of Aconiti
tuber (0.1 g/kg) reduced the bortezomib-induced mechanical allo-
dynia to the same level as GJG (1 g/kg, p.o.). These results suggest
that Aconiti tuber is one of active ingredient in the anti-allodynic
effect of GJG. Though the dose of Aconiti tuber contained within
GJG (1 g/kg) is about 0.03 g/kg, Aconiti tuber at the dose of 0.03 g/kg
could not reduce the bortezomib-induced mechanical allodynia.
Fig. 3. Effects of nor-binaltorphimine on the anti-allodynic effects of Goshajinkigan (GJG) (A) and processed Aconiti tuber (B) in von Frey test in rats. Bortezomib (0.2 mg/kg) was
administered i.p. twice a week for 2 weeks (on days 1, 4, 8, and 11) and drug evaluation was carried on days 12e15. GJG (1 g/kg), Aconiti tuber (0.1 g/kg) or vehicle (distilled water)
was administered p.o. 60 min before the test. Nor-binaltorphimine (nor-BNI, 10 mg/body) was injected i.t. 15 min before the test. Values are expressed as the mean ± S.E.M. of 6e10
animals. **P < 0.01 compared with control, yP < 0.05, yyP < 0.01 compared with GJG alone or Aconiti tuber alone.
H. Higuchi et al. / Journal of Pharmacological Sciences 129 (2015) 196e199198Suzuki et al. (9) reported that the extracts of Alismatis rhizoma or
Dioscoreae rhizoma, ingredients of GJG, exhibited the anti-
nociceptive effects in diabetic mice. Therefore, Alismatis rhizoma
and Dioscoreae rhizoma might be other active ingredients in the
anti-allodynic effect of GJG.
In this study, the single administration of tramadol exhibited
anti-allodynic effect on the bortezomib-induced mechanical allo-
dynia. Tramadol inhibits serotonin and noradrenaline reuptake,
and stimulates mu opioid receptors. The anti-allodynic effect of
tramadol is thought to be due to activation in the descending pain
inhibitory system (10). On the other hand, we found that kappa
opioid receptor antagonist nor-binaltorphimine completely
reversed the increase in withdrawal threshold by GJG or Aconiti
tuber. These ﬁndings suggest that kappa opioid receptor is involved
in the anti-allodynic effects of GJG and Aconiti tuber on the
bortezomib-induced mechanical allodynia. It has been reported
that an endogenous ligand dynorphin enhances dopaminergic
transmissions in hypothalamic arcuate nucleus by stimulating
spinal kappa opioid receptors (11,12). The activation exerts anti-
nociceptive effect via descending pain inhibitory system. Further-
more, the antinociceptive effects of GJG and Aconiti tuber have been
reported to be reduced by treatment with not only nor-
binaltorphimine but also anti-dynorphin antiserum in diabetic
and repeated cold stress mice (4,13), indicating that GJG and Aconiti
tuber increase the dynorphin release and then stimulate spinal
kappa opioid receptors. Though the animal model and evaluation
method in this study differ from those in previous reports (4,13),
themechanismmediating antinociceptive effects of GJG and Aconiti
tuber is thought to be essentially the same.
Pregabalin and tramadol have been reported to induce con-
stipation, nausea or somnolence as side effects (14,15). On the other
hand, GJG does not cause any adverse effects (3). In addition, GJG
has no negative impact on anti-tumor effect (3). Therefore, GJGmay
be able to be easily administered as a safe alternative.
In conclusion, the present study demonstrated for the ﬁrst time
that GJG reduces the bortezomib-induced mechanical allodynia,
and Aconiti tuber is one of active ingredient in the anti-allodynic
effect of GJG. Furthermore, this study indicated that kappa opioid
receptor is involved in the effect of GJG.Conﬂicts of interest
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